| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/01/2007 | US20070048307 Nucleotide sequences coding cytokine receptor for identifying modulators for treating blood disorders associated with cancer treatment |
| 03/01/2007 | US20070048306 Method for generating anti-variable region monoclonal antibodies |
| 03/01/2007 | US20070048305 CD147 binding molecules as therapeutics |
| 03/01/2007 | US20070048304 Method of treating allergy using antibody against human interleukin-5 receptor alpha chain |
| 03/01/2007 | US20070048303 Nucleic acid encoding cytokine receptor zcytor17 |
| 03/01/2007 | US20070048302 Interleukin-2 (IL-2); treating metastatic cancer, autoimmune disorders, and viral infections such as HIV by administering a peptide that peptide binds to the IL-2 beta chain |
| 03/01/2007 | US20070048301 Compositions and methods for the treatment of immune related diseases |
| 03/01/2007 | US20070048300 Antibodies having altered effector function and methods for making the same |
| 03/01/2007 | US20070048299 Methods of inducing an immune response |
| 03/01/2007 | US20070048298 administering nucleoproteins such as retinoblastoma associated protein 48 suppressor or inhibitors, used for prophylaxis of Sjogren's syndrome, as diagnostic agents or screening antiapoptosic agents |
| 03/01/2007 | US20070048297 Human secreted proteins |
| 03/01/2007 | US20070048287 Molecular antigen array |
| 03/01/2007 | US20070048283 Exposing to immunogenic portion of protein and/or encoding nucleotide homologenous to sequence 20 or 22b; eliciting response to 74P3B3 protein; pancreatic cancer |
| 03/01/2007 | US20070048281 Vaccination with a synergistic combination of a Hepatitis C Virus E1 vaccine and an antiviral agent, such as an interferon; improved immunostimulation |
| 03/01/2007 | US20070048277 Homogeneous preparations of il-28 and il-29 |
| 03/01/2007 | US20070048276 Homogeneous preparations of il-28 and il-29 |
| 03/01/2007 | US20070048275 Hepatitis C; antiviral polypeptide |
| 03/01/2007 | US20070048274 Homogeneous preparations of IL-28 and IL-29 |
| 03/01/2007 | US20070048273 Methods of treating cancer using IL-21 |
| 03/01/2007 | US20070048270 Methods of treating cancer using il-21 |
| 03/01/2007 | US20070048269 Methods of treating cancer using il-21 |
| 03/01/2007 | US20070048268 Methods of treating cancer using il-21 |
| 03/01/2007 | US20070048267 Methods of treating cancer using il-21 |
| 03/01/2007 | US20070048264 Methods of treating cancer using il-21 and monoclonal antibody therapy |
| 03/01/2007 | US20070048261 Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases |
| 03/01/2007 | US20070048227 Multispecific noncovalent complexes for delivery of therapeutics |
| 03/01/2007 | US20070048223 Cytokine receptor zcytor17 multimers |
| 03/01/2007 | US20070048222 Cytokine receptor zcytor17 multimers |
| 03/01/2007 | US20070048221 Antibodies that bind both bcma and taci |
| 03/01/2007 | US20070048220 Antibodies that bind both bcma and taci |
| 03/01/2007 | US20070048219 drug/polymer and biological conjugates/, used as angiogenesis inhibitors, for diagnosis and therapy of vision disorders |
| 03/01/2007 | US20070048218 Compositions and Methods for the Diagnosis and Treatment of Tumor |
| 03/01/2007 | CA2808168A1 Stem cell fusion model of carcinogenesis |
| 03/01/2007 | CA2620447A1 Combinations comprising dmxaa for the treatment of cancer |
| 03/01/2007 | CA2620436A1 Combinations comprising dmxaa for the treatment of cancer |
| 03/01/2007 | CA2620416A1 Zwitterionization of capsular saccharides |
| 03/01/2007 | CA2620306A1 Devices, compositions and methods for the protection and repair of cells and tissues |
| 03/01/2007 | CA2620074A1 Canine influenza vaccines |
| 03/01/2007 | CA2619825A1 Proteolysis resistant antibody preparations |
| 03/01/2007 | CA2619654A1 Combination therapies for inhibiting integrin-extracellular matrix interactions |
| 03/01/2007 | CA2619491A1 Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
| 03/01/2007 | CA2619406A1 Nogo receptor polypeptides and polypeptide fragments and uses thereof |
| 03/01/2007 | CA2619052A1 Anti-il-23 antibiodies |
| 03/01/2007 | CA2618482A1 Dual variable domain immunoglobin and uses thereof |
| 03/01/2007 | CA2615761A1 Humanized anti-ca6 antibodies and methods of using the same |
| 03/01/2007 | CA2615560A1 Compositions and methods to control angiogenesis with cupredoxins |
| 02/28/2007 | EP1757937A2 Antagonists of HMG1 for treating inflammatory conditions |
| 02/28/2007 | EP1757701A1 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 02/28/2007 | EP1757697A2 Group B streptococcus antigens |
| 02/28/2007 | EP1757696A2 Group B streptococcus proteins, and their use |
| 02/28/2007 | EP1757695A2 Prostate-specific membrane antigen |
| 02/28/2007 | EP1757694A2 Prostate-specific membrane antigen |
| 02/28/2007 | EP1757689A2 Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
| 02/28/2007 | EP1757686A1 Cell death inducer |
| 02/28/2007 | EP1757681A1 Tolerizing allografts of pluripotent stem cells |
| 02/28/2007 | EP1757622A1 Bivalent IgY antibody constructs for diagnostic and therapeutic applications |
| 02/28/2007 | EP1757621A2 Compositions and methods for the treatment and diagnosis of immune disorders |
| 02/28/2007 | EP1757618A2 Angiogenesis-associated proteins, and nucleic acids encoding the same |
| 02/28/2007 | EP1757617A1 Ret Ligand (RetL) for stimulating neural and renal growth |
| 02/28/2007 | EP1757615A1 Fusion protein for inhibiting cervical cancer |
| 02/28/2007 | EP1757311A2 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 02/28/2007 | EP1757306A1 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 02/28/2007 | EP1757305A2 Individualized anti-cancer antibodies |
| 02/28/2007 | EP1757304A1 Pharmaceutical composition and its use for the prophylactic or therapeutic treatment of retroviral diseases |
| 02/28/2007 | EP1757295A1 Peripheral-Type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer |
| 02/28/2007 | EP1757269A2 Pulmonary formulation comprising silicon particles |
| 02/28/2007 | EP1756576A1 Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 10 (dpp10) |
| 02/28/2007 | EP1756569A1 Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis |
| 02/28/2007 | EP1756287A2 Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof |
| 02/28/2007 | EP1756270A2 Diagnosis and treatment of myeloid and lymphoid cell cancers |
| 02/28/2007 | EP1756165A2 Tissue-specific imaging and therapeutical agents targeting proteins expressed on lung endothelial cell surface |
| 02/28/2007 | EP1756164A2 Dr5 antibodies and uses thereof |
| 02/28/2007 | EP1756163A2 Method of treating granuloma annulare or sarcoid |
| 02/28/2007 | EP1756161A2 Anti-il-13 antibodies, crystals of anti-il-13 antibodies and of complexes comprising them |
| 02/28/2007 | EP1756150A2 Group 1 mite polypeptide variants |
| 02/28/2007 | EP1756149A1 Live, oral vaccine for protection against shigella dysenteriae serotype 1 |
| 02/28/2007 | EP1756147A2 Peptides for inducing a ctl and/or htl response to hepatitis c virus |
| 02/28/2007 | EP1756143A1 Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same |
| 02/28/2007 | EP1755677A2 High pressure spray-dry of bioactive materials |
| 02/28/2007 | EP1755673A2 Anti-il-9 antibody formulations and uses thereof |
| 02/28/2007 | EP1755672A2 Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| 02/28/2007 | EP1755671A1 Therapy of platinum-resistant cancer |
| 02/28/2007 | EP1755670A2 Methods for treating vascular disease |
| 02/28/2007 | EP1755669A2 Methods and compositions for specifically targeting human hepatocellular carcinoma cells |
| 02/28/2007 | EP1755668A2 Adjuvants |
| 02/28/2007 | EP1755667A2 Stable peptide mimetic of hiv gp41 fusion intermediate |
| 02/28/2007 | EP1755666A1 Vaccine compositions comprising virosomes and a saponin adjuvant |
| 02/28/2007 | EP1755664A2 Prrsv subunit vaccines |
| 02/28/2007 | EP1755663A2 Neisserial vaccines |
| 02/28/2007 | EP1755662A2 Combined meningococcal conjugates with common carrier protein |
| 02/28/2007 | EP1755660A2 Method for enhancing or inhibiting insulin-like growth factor-i |
| 02/28/2007 | EP1755659A2 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| 02/28/2007 | EP1755658A2 Human complement c3 derivates with cobra venom factor-like function |
| 02/28/2007 | EP1755657A2 Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy |
| 02/28/2007 | EP1755653A2 Treatment methods utilizing albumin-binding proteins as targets |
| 02/28/2007 | EP1755645A2 Vegf inhibitors for the treatment of malignant pleural effusion |
| 02/28/2007 | EP1755642A1 Annexin v for preventing atherothrombois and plaque rupture |
| 02/28/2007 | EP1755641A2 Agonists and antagonists of p28, ebi3 and wsx/tccr for treating immune disorders |
| 02/28/2007 | EP1755628A1 Lactic bacteria and their use in the prevention of diarrhea |
| 02/28/2007 | EP1755626A1 USES OF BISPECIFIC ANTIBODY (Biab) COATED DENDRITIC CELLS PULSED WITH ANTIGENS |